Altimmune diskutieren
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at B. Riley from $20.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its price target lowered by analysts at UBS Group AG from $26.00 to $24.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune, Inc. (NASDAQ: ALT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune (NASDAQ:ALT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune (ALT) had its price target lowered by B. Riley Financial, Inc. from $18.00 to $13.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune (ALT) had its price target raised by HC Wainwright from $12.00 to $25.00. They now have a "buy" rating on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune (ALT) is now covered by Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Altimmune (ALT) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for ALT provided by MarketBeat
Altimmune (ALT) is now covered by Leerink Partners. They set an "outperform" rating and a $10.00 price target on the stock.
Ratings data for ALT provided by MarketBeat
Neueste Beiträge
Royal_Bank_of_Canada in Verastem Inc. diskutieren